Key result
This abstract describes the protocol for a prospective observational cohort study evaluating the prognostic value of heart rate variability in patients with STEMI; no results are reported.
Why the study?
Heart rate variability may have independent prognostic value in STEMI, but literature data regarding HRV assessment in this setting remain limited.
Does heart rate variability (HRV) assessment predict adverse outcomes in adult patients presenting with STEMI undergoing primary PCI?
Cohort
No
Does heart rate variability (HRV) assessment predict adverse outcomes in adult patients presenting with STEMI undergoing primary PCI?
Short-term HRV monitoring during primary PCI may aid STEMI risk stratification; leaves open its independent prognostic value beyond standard models.
BACKGROUND: Heart rate variability (HRV) could have independent and critical prognostic values in patients admitted for ST segment elevation myocardial infarction (STEMI). There are limited data in the literature regarding HRV assessment in STEMI setting. Thus, we aim to investigate the potential correlations between HRV and adverse outcomes in a contemporary cohort of patients presenting with STEMI undergoing primary percutaneous coronary intervention (PCI). METHODS: We will perform a prospective, observational cohort study in a single healthcare center. Adult patients aged ≥18 years presenting with STEMI in sinus rhythm will be enrolled for primary PCI within 12 h from symptoms onset. Time domain, frequency domain, and nonlinear HRV parameters will be measured using a medically approved wrist-wearable device for 5 min segments during myocardial revascularization by primary PCI. Additional HRV measurements will be performed one and six months from the index event. The primary composite outcome will include all-cause mortality and major adverse cardiovascular events (during the hospital stay, one month, and one year following admission). Several secondary outcomes will be analyzed: individual components of the primary composite outcome, target lesion revascularization, hospitalizations for heart failure, ventricular arrhythmias, left ventricular ejection fraction, and left ventricular diastolic function. CONCLUSIONS: Our study will enlighten the reliability and usefulness of HRV evaluation as a prognostic marker in contemporary patients with STEMI. The potential validation of HRV as a risk marker for adverse outcomes following STEMI will ensure a background for including HRV parameters in future risk scores and guidelines.
No takes yet. Share an insight, caveat, or question.
Brinza et al. (2022) conducted a cohort in ST segment elevation myocardial infarction (STEMI). Heart rate variability (HRV) was evaluated on Composite of all-cause mortality and major adverse cardiovascular events (during the hospital stay, one month, and one year following admission). This abstract describes the protocol for a prospective observational cohort study evaluating the prognostic value of heart rate variability in patients with STEMI; no results are reported.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: